Jason C. Sniffen, D.O., F.A.C.O.I., F.A.C.P., F.I.D.S.A.

Dr. Sniffen has practiced infectious diseases in the Orlando area since 2001. He is the immediate past President of Infectious Disease Consultants, MD PA, one of the busiest infectious diseases practices in the United States.

After completing his fellowship training in infectious diseases at the University of South Florida, College of Medicine in Tampa, Florida, Dr. Sniffen relocated to Orlando. He continues as a Clinical Assistant Professor in the Department of Infectious Diseases at South Florida College of Medicine. Additionally, Dr. Sniffen teaches medical students, residents, and fellows from Advent Health System’s many training programs.

Dr. Sniffen is Board Certified in Infectious Diseases, Internal Medicine and Hyperbaric Medicine. He is the current Chair of ID for the Advent Health System. Dr. Sniffen has served as Chief of Staff, Chief Medical Advisor, Chair of the Pharmacy and Therapeutics Committee within the system. He currently serves on the Physicians’ Health Advisory Committee and the Antibiotic Stewardship Committee for Advent Health System in Orlando.

Dr. Sniffen is a Fellow of the American College of Physicians, American College of Osteopathic internists and has earned the prestigious title of “Fellow of the Infectious Disease Society of America, (FIDSA).”

Dr. Sniffen has been repeatedly named to the “Finest Doctors in Orlando” by the Orlando Magazine. At the national level, Dr. Sniffen is past chairman of the American Osteopathic Board of Internal Medicine (AOBIM) and past chairman of the ID Section of the board, a position he held for 11 years and continues to serve as an adviser. Dr. Sniffen has dozens of publications to his credit in medical journals, textbooks, and online.

Dr. Sniffen has received multiple awards of excellence in medicine during his career and was a graduate of the Inaugural Physician Leadership Program at Advent Health System.

Recent Publications

McFarland LV, Hecht G, Sanders ME, Goff DA, Goldstein EJC, Hill C, Johnson S, Kashi MR, Kullar R, Larco ML, Merenstein DJ, Millette M, Preidis GA, Quigley EMM, Reid G, Salminen S, Sniffen JC, Sokol H, Szajewska H, Tancredi DJ, Woolard K. Recommendations to improve quality of probiotic systematic reviews with meta-analyses: Developed by expert Delphi consensus. JAMA Network Open. 2023; in press.

Park SY, Lindner MS, Brick K, Noll N, Ounit R, Noa LJ, Sabzwari R, Trible R, Sniffen JC, Roth P, Khan A, Rodriguez A, Sahra S, Davis MJ, Brar IS, Balasundaram G, Nolte FS, Blauwkamp TA, Perkins BA, Bercovici S. Detection of Mpox Virus Using Microbial Cell-free DNA: the Potential of Pathogen-Agnostic Sequencing for Rapid Identification of Emerging Pathogens. J. Infect. Dis. 2023; in press.

Kullar, K, Chisari, E, Snyder, J, Cooper, C, Parvizi, J, Sniffen, J. Next- Generation Sequencing Supports Targeted Antibiotic Treatment for Culture Negative Orthopedic Infections. Clin Infect Dis 2022.

Marinucci V, Carr AL, Hayes J, Lopez-Ruiz A, Sniffen J, Louzon PR. Pharmacist driven Methicillin Resistant S. aureus polymerase chain reaction testing for pneumonia. Annals of Pharmacotherapy 2022.

Louzon PR, Marinucci V, Carr A, Hayes J, Sniffen J, Lopez-Ruiz A.. Pharmacist driven Methicillin Resistant S. aureus polymerase chain reaction testing for pneumonia. Critical Care Medicine 2022; 50(1): 695.

McFarland, Lynne V. PhD; Kullar, Ravina PharmD; Johnson, Stuart MD; Sniffen, Jason C. DO; Woolard, Kristin APRN; Goldstein, Ellie J.C. MD. Why Do ACG and AGA Guidelines Differ for the Use of Probiotics and the Prevention of CDI?. The American Journal of Gastroenterology 117(3):p 501, March 2022. | DOI: 10.14309/ajg.0000000000001567

Maziade PJ, Ship N, Sniffen JC, Goldstein EJC. Enhanced Clostridiodies difficile infection prevention with a pharmacy-controlled policy that adds a three-strain Lactobacillus probiotic concomitantly to antibiotic therapy. Clin Infect Dis 2021; 73:1524–7.

Mandzhieva B, Lackey A, Sniffen J, Kameh D, Maharam E. Small bowel perforation caused by disseminated mucormycosis. Consultant. Published online August 30, 2021. doi:10.25270/con. 2021.08.00013

Eduardo Oliveira, Amay Parikh, Arnaldo Lopez-Ruiz, Maria Carrilo, Joshua Goldberg, Martin Cearras, Khaled Fernainy, Sonja Andersen, Luis Mercado, Jian Guan, Hammad Zafar, Patricia Louzon, Amy Carr, Natasha Baloch, Richard Pratley, Scott Silverstry, Vincent Hsu, Jason Sniffen, Victor Herrera, Neil Finkler. ICU outcomes and survival in patients with severe COVID-19 in the largest health care system in central Florida. PLoS One. 2021 Mar 25;16(3):e0249038. doi:10.1371/journal.pone.0249038. eCollection 2021.

Davide Ventura, Amy L Carr, R Duane Davis, Scott Silvestry, Linda Bogar, Nirav Raval, Cynthia Gries, Jillian Hayes, Eduardo Oliveira, Jason Sniffen, Steven Allison, Victor Herrera, Douglas Jennings, Robert L Page, II, John F McDyer, Christopher R Ensor. Renin Angiotensin Aldosterone System Antagonism in 2019 Novel Coronavirus Acute Lung Injury. Open Forum Infectious Diseases, Volume 8, Issue 10, October 2021, ofab170, https://doi.org/10.1093/ofid/ofab170

Ballantyne E, Carr A, Ensor C, Sniffen J, Minor S, Lopez-Ruiz A, Subedi B, Louzon P, Wooten L. Interleukin-6 (IL-6) Receptor Antagonism with Tocilizumab for COVID-19 Related Cytokine Release Syndrome (CRS): Initial Outcomes. Poster presented at MAD-ID 2021; May 2021; Virtual.

Enhanced Clostridioides difficile infection prevention with a pharmacy-controlled policy that adds a three-strain Lactobacillus probiotic concomitantly to antibiotic therapy. Maziade PJ, Ship N, Sniffen JC, Goldstein EJC. Clin Infect Dis. 2021 May 9:ciab414. doi: 10.1093/cid/ciab414. Online ahead of print.PMID: 33966076

Reducing collateral damage associated with antibiotic treatment: do less harm. Sniffen JC. Clin Infect Dis. 2015 May 15;60 Suppl 2:S65. doi: 10.1093/cid/civ176.PMID: 25922402 No abstract available.

Sniffen JC, McFarland LV, Evans CT, Goldstein EJC (2018) Choosing an appropriate probiotic product for your patient: An evidence- based practical guide. PLoS ONE 13(12): e0209205. https://doi.org/10.1371/journal. pone.0209205. Received: August 2, 2018 Accepted: November 30, 2018 Published: December 26, 2018.

Goldstein EJ, Johnson SJ, Maziade PJ, Evans CT, Sniffen JC, Millette M, et al. Probiotics and prevention of Clostridium difficile infection. Anaerobe. 2017; 45:114–119. https://doi.org/10.1016/j.anaerobe. 2016.12.007 PMID: 27988389http://dx.doi.org/10.1016/j.anaerobe.2016.12.007

Reducing Collateral Damage Associated With Antibiotic Treatment: Do Less Harm Jason C. Sniffen Clinical Infectious Diseases, Volume 60, Issue suppl_2, 15 May 2015, Pages S65, https://doi.org/10.1093/cid/civ176

<< Return to Main Physicians Page